EGFR and non-small cell lung carcinoma: Metastatic NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) have exhibited an improved survival outcome6 and the EGFR-TKIs are standard drugs in first-line treatment7.